VERV / Verve: Spiffy Biotech That Cathie Wood Bought, Initiating With A Hold Rating

Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revision more_horizontal

Company to hold investor event in conjunction with data presentation on November 12, 2023 Company to hold investor event in conjunction with data pres more_horizontal

Verve Therapeutics (VERV) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to l more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Verve Therapeutics (VERV). While the effectiveness o more_horizontal

Cathie Wood has been buying a lot of Verve Therapeutics stock recently. It's a gene-editing biotech that's just starting its first clinical trials. more_horizontal

Verve, which was founded in 2018 and went public in June 2021, is developing gene-editing treatments, delivered through a single, intravenous infusion more_horizontal

Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease. more_horizontal

Verve Therapeutics (VERV) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to l more_horizontal